BV100

Phase 3Small molecule

BBioVersys AG

BV100 is one of 45 small molecule programs targeting Bacterial Pneumonia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bacterial PneumoniaActive, not recruiting

Bacterial PneumoniaPhase 3

Active, not recruiting

Competition

Competitive Landscape

54 competitors in Bacterial Pneumonia

#DrugCompanyPhaseTrials

Teflaro

AbbVie

Approved

3 2

Biaxin

AbbVie

Approved

1 3

Ketek

Levaquin

2 5

Avelox

Bayer

Phase 3

5 6

Zyvox

Pfizer

Phase 3

4 7

Tygacil

PPrism Pharmaceuticals

Approved

—8

Avycaz

PPhiladelphia Eye Associates

Amikin

Cipro

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 3Not yet recruiting

Bacterial Pneumonia

NCT07326540

Q3 2028

Phase 2Not yet recruiting

Acinetobacter Baumannii

NCT07431307

Clinical

Trials by Indication[1]

Clinical Trial2 trials

Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of BV100 in Healthy Male Subjects

Completed·BBioVersys AG·Phase 1·NCT05087069·16 enrolled

Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of BV100 in Male Subjects

Completed·BBioVersys AG·Phase 1·NCT04636983·54 enrolled

Midazolam1 trial

A Study to Assess Effect of BV100 on the Pharmacokinetics of Midazolam in Healthy Participants

Completed·BBioVersys AG·Phase 1·NCT05537090·16 enrolled

Intravenous Administration1 trial

Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100

Completed·BBioVersys AG·Phase 1·NCT05684705·35 enrolled

Hepatic Impairment1 trial

A Study to Assess the Phamacokinetics of BV100 in Participants with Varying Degrees of Hepatic Impairment

Completed·BBioVersys AG·Phase 1·NCT05537142·33 enrolled

Bacterial Pneumonia1 trial

Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex

Not yet recruiting·BBioVersys AG·Phase 3·NCT07326540·248 enrolled

4 more indications

Tics1 trial

To Evaluate the Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of BV100

Completed·BBioVersys AG·Phase 1·NCT05684718·16 enrolled

TED1 trial

PK of BV100 in Patients VABP Suspected or Confirmed to Be Due to CRAB

Completed·BBioVersys AG·Phase 2·NCT05685615·39 enrolled

Acinetobacter Baumannii1 trial

Safety, Pharmacokinetics and Efficacy of BV100 Plus Low Dose Polymyxin B Plus Ceftazidime/Avibactam, or Plus Cefiderocol in Patients With Pulmonary and Extrapulmonary Infections Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex

Not yet recruiting·BBioVersys AG·Phase 2·NCT07431307·120 enrolled

Renal Impairment1 trial

Pharmacokinetics and Safety of BV100 Administered as Single Intravenous Infusion to Subjects With Renal Impairment

Completed·BBioVersys AG·Phase 1·NCT05086107·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for BV100. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BV100 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BV100. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BioVersys AG company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBioVersys AG

BV100

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q3 2028

Trials by Indication[1]

Clinical Trial2 trials

Midazolam1 trial

Intravenous Administration1 trial

Hepatic Impairment1 trial

Bacterial Pneumonia1 trial

Tics1 trial

TED1 trial

Acinetobacter Baumannii1 trial

Renal Impairment1 trial

References

Drug Info

Quick Facts

Related News